Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Alpine Immune Sciences Inc.
Headquarters: Seattle, WA, United States of America
Website: N/A
Year Founded: 2015
Status: Acquired
BioCentury | Jan 11, 2025
Management Tracks
Faces in new places ahead of JPM: Rubin joining Guggenheim
Week’s management moves include new venture partners at Frazier and updates from Beigene, Intellia and more
BioCentury | Jul 31, 2024
Data Byte
I&I buying spree continues
2024 has already brought half a dozen M&A deals over $1B targeting immunology and inflammation
BioCentury | Jul 23, 2024
Management Tracks
Armstrong takes new role at Dana-Farber
Plus: The Carlyle Group’s Rubenstein to join Moderna’s board and updates from Geron, Vedanta, Vericel, Metrion and PharmaEssentia
BioCentury | May 30, 2024
Product Development
Renal therapies get disease-specific
Endpoint innovation and success stories are driving a surge in renal disease drug development
BioCentury | May 28, 2024
Deals
Asahi Kasei rides renal momentum with $1.1B Calliditas takeout
Deal gives Japanese pharma Tarpeyo, first drug approved to treat IgA nephropathy
BioCentury | May 22, 2024
Deals
Biogen’s ‘pick and choose’ strategy in immunology leads to $1B HI-Bio takeout
Continuing diversity push under Viehbacher, Biogen obtains two programs spun out from MorphoSys, backed by Arch, Monograph, Jeito and others
BioCentury | Apr 16, 2024
Deals
Vertex’s Alpine buy, Goldman’s venture & IRA tea leaves: a BioCentury podcast
Plus: A look at BioCentury’s new R&D conference, Grand Rounds
BioCentury | Apr 16, 2024
Deals
Deals report: Vertex’s biggest deal yet, and more
Novartis gets two androgen receptor protein degraders from Arvinas and Genentech-Adaptimmune terminate allogeneic T cell therapy deal
BioCentury | Apr 12, 2024
Deals
In $4.9B Alpine deal, Vertex sees best-in-class therapy with room for label expansions
Buyer believes povetacicept can outshine others in BAFF/APRIL class, even if not first to market — and can become a pipeline-in-a-product
BioCentury | Dec 13, 2023
Data Byte
November follow-ons: Xenon raises more than one third of month’s total
Eight biopharmas brought in a combined $949M in follow-on financing; nearly all had gained value by the end of the month
Items per page:
1 - 10 of 41